Table 1.

Demographics and baseline disease characteristics for patients who did and did not receive first subsequent CT in PALOMA-2 by treatment arm.

	Without First Subsequent CT		With First Subsequent CT
	PAL + LET	PBO + LET	PAL + LET	PBO + LET
	(n = 361)	(n = 171)	(n = 83)	(n = 51)
Age, median, y	63.0	61.0	59.0	61.0
< 65, n (%)	206 (57.1)	108 (63.2)	57 (68.7)	33 (64.7)
≥ 65, n (%)	155 (42.9)	63 (36.8)	26 (31.3)	18 (35.3)
Race,*n (%)
White	275 (76.2)	130 (76.0)	69 (83.1)	42 (82.4)
Black	6 (1.7)	3 (1.8)	2 (2.4)	0
Asian	55 (15.2)	25 (14.6)	10 (12.0)	5 (9.8)
Other	25 (6.9)	13 (7.6)	2 (2.4)	4 (7.8)
Weight, median, kg	67.3	66.7	71.2	67.0
Disease site, n (%)
Visceral	167 (46.3)	76 (44.4)	47 (56.6)	34 (66.7)
Nonvisceral	194 (53.7)	95 (55.6)	36 (43.4)	17 (33.3)
Disease-free completion of prior (neo)adjuvant therapy, n (%)
De novo metastatic	141 (39.1)	65 (38.0)	26 (31.3)	16 (31.4)
DFI ≤ 12 mo	69 (19.1)	33 (19.3)	29 (34.9)	15 (29.4)
DFI > 12 mo	151 (41.8)	73 (42.7)	28 (33.7)	20 (39.2)
Nature of prior (neo)adjuvant anticancer therapy, n (%)
Prior systemic therapy
No	141 (39.1)	65 (38.0)	26 (31.3)	16 (31.4)
Yes	220 (60.9)	106 (62.0)	57 (68.7)	35 (68.6)
Prior CT for primary diagnosis, n (%)
No	194 (53.7)	92 (53.8)	37 (44.6)	21 (41.2)
Yes	167 (46.3)	79 (46.2)	46 (55.4)	30 (58.8)
Neoadjuvant	39 (10.8)	23 (13.5)	15 (18.1)	9 (17.6)
Adjuvant	143 (39.6)	64 (37.4)	37 (44.6)	25 (49.0)
Prior hormonal therapy for primary diagnosis, n (%)
No	163 (45.2)	77 (45.0)	31 (37.3)	19 (37.3)
Yes	198 (54.8)	94 (55.0)	52 (62.7)	32 (62.7)
Prior hormonal therapies, n (%)
1	128 (35.5)	62 (36.3)	30 (36.1)	25 (49.0)
> 1	70 (19.4)	32 (18.7)	22 (26.5)	7 (13.7)

CT = chemotherapy; DFI = disease-free interval; LET = letrozole; PAL = palbociclib; PBO = placebo.

*Other includes not reported/missing patients.